Meetup Unveils Fresh New Design as Gen Z and Millennials Crave More In-Person Interactions
30.9.2025 15:00:00 CEST | Business Wire | Press Release
Meetup, the digital platform that has been connecting people in real life for more than two decades, has just unveiled a significant redesign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930663024/en/
Before & After of the Meetup home page after log in, featuring the updated visual identity and improved navigation and content discovery.
Combining lively visuals with a streamlined experience, the new look marks Meetup’s biggest design evolution to date and signals a firm belief in the platform’s continued growth and bright future. As of today, Meetup’s new design is live on Web, with Mobile coming soon.
About the new design
The redesign introduces an updated visual identity that better captures the essence of Meetup—people coming together and building human connections through fun and meaningful experiences. To this end, the new look features more high-quality photography that celebrates people in real-life scenarios, as well as a new logo, brighter color palette, updated fonts, and expressive new icons.
The interface is also now even more user-friendly: The layout has been refined with better spacing, stronger contrast, and clearer hierarchies to improve readability. Navigation and content discovery have been simplified so that both members and organizers can find what they need with fewer clicks.
“We wanted to make Meetup feel even more inviting and intuitive, while celebrating the visual elements that can play a huge part in conveying the energy of a community,” explained Alex Landra, the Meetup product designer leading the effort. “The experience of connecting with other people begins the moment you arrive on the platform, and we want it to be as smooth and enjoyable as possible right from the start.”
The full redesign follows previous groundwork in updating critical aspects of the Meetup experience, such as a new Mobile layout for the page where members can explore and discover events. Since launching the update, RSVPs from that page jumped by 20%—showing that improvements to the digital experience can spark more real-world connections.
Bridging the old and the new
Adult Gen Z and young Millennials now represent some of Meetup’s most engaged users, accounting for 40% of monthly active users and representing the most active age group globally. In an era of digital fatigue and isolation, Meetup has become a trusted way for this generation to find face-to-face experiences.
“It’s inspiring to see so many young people drawn to a platform that started before some of them were even born,” said Chiara Vivaldi, product lead at Meetup. “We wanted the new look to resonate with our younger audience while honoring the spirit of Meetup and the community who’ve made it thrive, making it warmer and more welcoming for everyone who uses it.”
So while the look of the platform feels new, the core experience remains unchanged. Essential navigation and the logic of how organizers and members plan and discover events and groups work just as they always have.
A step in a series of Meetup improvements
Since joining the Bending Spoons suite of digital products in 2024, Meetup has rolled out a series of improvements to enhance the experience for both members and organizers. Notable examples include Meetup Starter, the platform’s first-ever free plan for new organizers, as well as AI-powered recommendations for more personalized event discovery. Further updates are described in a recent article on the Meetup blog.
These efforts have contributed to +20% year-over-year growth in new registrations.
About Meetup
Meetup is the leading platform for finding and building local communities. Since its launch in 2002, it has helped millions of people around the world connect over shared interests and passions. From professional networking to creative pursuits to outdoor adventures, Meetup makes it easy to organize, discover, and attend events that matter.
About Bending Spoons
Bending Spoons has served a billion people across the globe through its suite of digital technology businesses, including Evernote, Meetup, komoot, Remini, StreamYard, and WeTransfer. Its products are currently used by more than 300 million people and 10 million paying customers each month.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930663024/en/
Contacts
Media contact
Rebecca Shamritsky
rshamritsky@meetup.com
Media contact
Christy Keenan
ck@bendingspoons.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom